```html

Jellyfish Toxicity Syndrome

Overview

Jellyfish Toxicity Syndrome (JTS) is a systemic reaction that can occur after a person is stung by certain species of jellyfish, most notably the box jellyfish (*Chironex fleckeri*), the lion’s‑mane jellyfish (*Cyanea capillata*), and the Portuguese man‑of‑war (*Physalia physalis*). While most stings cause localized pain and skin irritation, JTS describes a constellation of signs that indicate the venom has entered the bloodstream and is affecting multiple organ systems.

JTS can affect anyone who comes into contact with a venomous jellyfish, but the highest risk groups are:

• Beachgoers, surfers, and divers in tropical and subtropical waters.
• Coastal workers (fishermen, lifeguards, marine biologists).
• Tourists on cruise ships or island resorts where jellyfish blooms are common.

Exact prevalence is difficult to determine because many stings are treated locally and never become systemic. However, epidemiologic data from Australia’s Queensland Health indicate that there are roughly 400–600 serious jellyfish envenomations each year, with about 5–10 % progressing to systemic toxicity (JTS) or fatal outcomes.<sup>[1] Queensland Health, 2022</sup> In the Philippines and other Indo‑Pacific nations, similar patterns have been reported, with mortality rates up to 15 % in the absence of rapid medical care.<sup>[2] WHO, 2021</sup>

Symptoms

Symptoms of JTS can develop within minutes to several hours after the initial sting. They are grouped into three major categories: cutaneous, cardiovascular/respiratory, and systemic (neurologic, renal, and gastrointestinal).

Cutaneous (skin) manifestations

• Immediate pain: Sharp, burning sensation at the site of contact.
• Linear or whiplash welts: Often called “flame‑like” lesions that follow the tentacle’s path.
• Vesicles or blisters: May appear 2–6 hours later, sometimes filled with clear fluid.
• Hyperpigmentation: Darkening of the skin that can persist for weeks.

Cardiovascular and respiratory signs

• Rapid heart rate (tachycardia) or arrhythmias: Palpitations, irregular beats.
• Hypotension: Sudden drop in blood pressure leading to dizziness or fainting.
• Shortness of breath: May progress to wheezing or respiratory distress.
• Chest pain: Can mimic myocardial infarction.

Neurologic symptoms

• Headache and confusion – early signs of systemic involvement.
• Muscle cramps or weakness – especially in the limbs.
• Seizures – rare but reported in severe envenomation.
• Altered mental status – ranging from lethargy to coma.

Renal and gastrointestinal effects

• Nausea, vomiting, abdominal pain – may appear within the first hour.
• Hematuria (blood in urine) or reduced urine output, indicating possible kidney involvement.
• Rhabdomyolysis – muscle breakdown that can lead to acute kidney injury.

Other systemic clues

• Fever – low‑grade, often a response to inflammation.
• Swelling of lips, tongue, or throat – sign of anaphylaxis‑like reaction.

Causes and Risk Factors

JTS is caused by the injection of neurotoxic and cytolytic proteins contained in the nematocysts (stinging cells) of certain jellyfish. The venom contains:

• Porins that form pores in cell membranes.
• Phospholipases that disrupt cell membranes.
• Neurotoxins that block sodium channels, leading to cardiac and neuronal dysfunction.

Key factors that increase the likelihood of developing JTS include:

• Species: Box jellyfish have the most potent venom; man‑of‑war stings are also high risk.
• Extent of exposure: Larger surface area covered by tentacles = more venom delivered.
• Delay in first aid: Not rinsing with vinegar (acetic acid) within the first 30 minutes increases nematocyst discharge.
• Pre‑existing conditions: Cardiovascular disease, asthma, or immunocompromise may worsen systemic response.
• Age: Children and the elderly are more vulnerable to rapid fluid shifts and cardiac effects.

Diagnosis

Diagnosing JTS is primarily clinical, based on a clear history of a jellyfish sting and the presence of systemic signs. However, several investigations help assess severity and guide treatment.

History and Physical Examination

• Time and location of the sting (identifying the species when possible).
• Character of skin lesions and progression.
• Vital signs: heart rate, blood pressure, respiratory rate, oxygen saturation.
• Neurologic assessment: mental status, cranial nerve function, motor strength.

Laboratory Tests

• Complete blood count (CBC): Look for leukocytosis or hemoconcentration.
• Serum electrolytes & renal panel: Detect hyperkalemia, rising creatinine.
• Creatine kinase (CK): Elevated >5,000 U/L suggests rhabdomyolysis.
• Cardiac enzymes (troponin I/T): May rise with myocardial injury.
• Coagulation profile: Prolonged PT/aPTT can indicate venom‑induced coagulopathy.

Electrocardiogram (ECG) and Continuous Cardiac Monitoring

Essential for detecting arrhythmias, conduction blocks, or ST‑segment changes.

Imaging (if indicated)

• Chest X‑ray – to assess pulmonary edema or pleural effusion.
• Abdominal ultrasound – if renal involvement is suspected.

Specialized Tests (research settings)

Enzyme‑linked immunosorbent assay (ELISA) for jellyfish venom antibodies exists but is not routinely available in emergency departments.

Treatment Options

Management of JTS is time‑critical and follows a stepwise approach: first aid, emergency stabilization, specific antivenom (where available), and supportive care.

First‑Aid Measures (administered in the field)

1. Vinegar (4 % acetic acid): Pour over the sting area for at least 30 seconds to inactivate unfired nematocysts. Do NOT rub the area – this can cause more discharge.
2. Remove tentacles: Use tweezers or the edge of a credit card; avoid bare hands.
3. Do NOT use fresh water or urine: Osmotic changes trigger further nematocyst discharge.
4. Call emergency services immediately.

Emergency Department (ED) Management

1. Airway, Breathing, Circulation (ABCs): Provide supplemental oxygen, secure airway if swelling is present.
2. Intravenous (IV) access: Large‑bore cannulas for fluid resuscitation.
3. Fluids: Crystalloid bolus 20 mL/kg to counteract hypotension and prevent renal injury.
4. Analgesia: IV opioids (e.g., morphine) for severe pain; consider ketamine in hemodynamically unstable patients.
5. Antihistamines & corticosteroids: Diphenhydramine 25–50 mg IV and methylprednisolone 1 mg/kg IV to mitigate inflammation and anaphylactoid response.
6. Antivenom (where available): – Australia has a box‑jellyfish antivenom (cP53). Dose 5–10 mL IV over 30 minutes, repeat if symptoms persist.<sup>[3] Australian Clinical Toxicology, 2023</sup>
7. Cardiac monitoring: Treat arrhythmias per ACLS guidelines; consider IV magnesium for torsades de pointes.
8. Renal protection: Maintain urine output >0.5 mL/kg/h; alkalinize urine with sodium bicarbonate if CK >5,000 U/L.
9. Seizure control: Lorazepam 0.1 mg/kg IV if needed.

Post‑Acute/Outpatient Care

• Gradual taper of steroids over 5‑7 days to prevent rebound inflammation.
• Physical therapy for muscle weakness or joint stiffness.
• Psychological support – some patients develop post‑traumatic stress after severe envenomation.
• Vaccination updates (e.g., tetanus) if skin integrity was compromised.

Living with Jellyfish Toxicity Syndrome

Although most people recover fully, a subset experiences lingering effects. The following strategies help optimize recovery and quality of life.

Daily Management Tips

• Hydration: Aim for ≥2 L of water daily to aid renal clearance.
• Skin care: Apply silicone gel sheets or scar‑reduction creams (e.g., silicone gel) to persistent hyperpigmentation.
• Pain control: Use acetaminophen or NSAIDs (if no renal contraindication) for mild lingering pain.
• Monitor vitals: Check resting heart rate and blood pressure weekly for the first month.
• Exercise cautiously: Begin with low‑impact activities (walking, swimming with a protective wetsuit) after clearance from a physician.
• Medication adherence: Finish any prescribed steroid taper or antihistamine regimen.

Psychosocial Support

Fear of returning to the water is common. Referral to a mental‑health professional for cognitive‑behavioral therapy (CBT) can reduce anxiety. Many coastal communities offer peer‑support groups for marine‑injury survivors.

Prevention

Preventing the sting in the first place is the most effective strategy.

• Wear protective clothing: Full‑body “stinger suits” or neoprene wetsuits (≥0.5 mm) reduce skin exposure.
• Check local advisories: Many beach authorities post jellyfish warnings; heed “red flag” alerts.
• Use barrier creams: Products containing zinc oxide or copper peptides have limited evidence but may provide a modest protective layer.
• Avoid peak bloom times: In Australia, box jellyfish are most common from November to May.
• Carry emergency vinegar kits: Small, sealed bottles can be kept in beach bags or on boats.
• Educate children and tourists: Brief safety talks before entering the water.

Complications

If JTS is not recognized or treated promptly, serious complications can develop.

• Cardiogenic shock: Resulting from severe arrhythmias or myocardial depression.
• Acute respiratory distress syndrome (ARDS): Due to fluid overload or direct pulmonary toxicity.
• Renal failure: From rhabdomyolysis, hemolysis, or direct tubular injury.
• Coagulopathy: Disseminated intravascular coagulation (DIC) can lead to bleeding.
• Neurologic sequelae: Persistent weakness, peripheral neuropathy, or cognitive deficits.
• Infections: Secondary bacterial infection of skin lesions.

When to Seek Emergency Care

Key Takeaways

• Jellyfish Toxicity Syndrome is a systemic reaction to potent jellyfish venom; it can be life‑threatening.
• Prompt first aid (vinegar) and rapid transport to medical care dramatically improve outcomes.
• Early recognition of cardiovascular, neurologic, or renal signs guides lifesaving interventions.
• Prevention—protective clothing, awareness of local jellyfish activity, and emergency kits—remains the cornerstone of public health.

---

References

1. Queensland Health. “Jellyfish Envenomation – Statistics and Management.” 2022.
2. World Health Organization. “Marine Envenomations: Global Burden and Recommendations.” 2021.
3. Australian Clinical Toxicology Society. “Box Jellyfish Antivenom: Indications and Outcomes.” 2023.
4. Mayo Clinic. “Jellyfish Stings – Symptoms and First Aid.” Updated 2024.
5. Cleveland Clinic. “Management of Marine Animal Venoms.” 2023.

```